InsidersTradesSigma
리메드 Stock: price and directors' dealings · South Korea · DART (FSS)
Follow the 리메드 share price and the full insider trade history of the company, a listed issuer based in South Korea. Shares are listed on KR KR, under the authority of DART (FSS). Operating in the Health Care sector, 리메드 has recorded 76 public disclosures. Market capitalisation: €83.1bn. The latest transaction was disclosed on 24 June 2026 (Other). Among the most active insiders: 이근용. All data is accessible without an account.
76
Insider Decl.
0
Thresholds
·
5 ops.
Buy Volume
·
0 ops.
Sell Volume
13Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental score
Ranked 18,507 of 26,270 companies
38.0
score / 100
Value30
Quality46
FCF yld1.9%
Earn yld0.7%
EV/EBITDA42.7x
ROE1.8%
Gross mgn57%
Net mgn2.1%
Debt/EBITDA2.7x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 24 June 2026
Declarations76 total
25 of 76 declarations
About 리메드
리메드 operates in the healthcare and pharmaceutical sector, listed on the XKRX market. The company focuses on developing innovative solutions to enhance healthcare.